Navigation Links
ClinStar to Present on Clinical Trial Recruitment in the Emerging Regions of Russia and Eastern Europe
Date:10/18/2011

SAN FRANCISCO, Oct. 18, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that President and CEO David Passov and Manager of Clinical Operations Alexander Kutermin will speak at Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference, November 3-4, in Philadelphia, PA.  

(Logo:  http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)

According to the International Agency for Research on Cancer's (a division of the World Health Organization) GLOBOCAN 2008 report, an estimated 12.7 million people worldwide are diagnosed with some form of cancer annually and this number is expected to jump to 21 million by 2030. The emerging markets of Russia, Ukraine, Belarus and the Baltics offer access to a population of more than five million cancer sufferers. By conducting clinical trials in these regions, biopharmaceutical companies can significantly speed enrollment, and thereby, reduce the overall time and cost to develop an oncology drug.  

During the presentation scheduled for Friday, November 4 at 1:30 p.m., Mr. Passov will explore perceptions and comparisons of emerging markets and discuss how to navigate cultural and regulatory challenges in the region in order to optimize recruitment. Mr. Kutermin will present a case study revealing how Russia, Ukraine, Belarus and the Baltics outperformed 20+ other countries in a global, Phase III breast cancer trial.  

Through a series of keynote regional presentations, case studies and interactive panel discussions, Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference will examine the current role that emerging regions play in conducting oncology clinical trials with a focus on the operational, regulatory and logistical challenges involved.  

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 260 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinStar to Present on Russias Performance as an Emerging Market in Global Clinical Trials
2. ClinStar to Present on Conducting Clinical Trials in Russia
3. ClinStar, LLC Establishes New Office on the US East Coast
4. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
5. Renessa® Treatment for Stress Incontinence: Three Year Clinical Results Presented
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
8. PLC Medical Systems CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
10. Ziehm Imaging Presents new 20 kW Ziehm Vision R
11. Amerigroup Foundation Presents Grant to Rx Partnership in Virginia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research entitled "Brain Computer Interface Market ... Forecast 2016 - 2024," the  global brain computer interface (BCI) ... bn by 2024. The market is estimated to expand ... period from 2016 to 2024. A BCI ...
(Date:5/4/2016)... -- Yissum Research Development Company of ... it had signed an exclusive world-wide licensing and research ... protein degradation and immunomodulatory drugs for cancer and immune ... representing first-in-class therapy for hematologic and solid malignancies. Financial ... The novel technology was developed by Yinon Ben-Neriah ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... Featured cast and ... unique keynote address at the 2016 Learning Summit , June 12-15, in ... college students. Their stories—of complicated family issues, financial difficulties, and other personal obstacles—are ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... reduce fat areas around the body, is the most popular among body sculpting ... released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of ...
(Date:5/6/2016)... ... May 06, 2016 , ... Canadian author Mark Black is a speaker, author, and ... Heart" around the world … with the help of his publisher Strategic Book Group and ... lay in a hospital bed waiting for a miracle: He needed a heart and double-lung ...
(Date:5/6/2016)... ... May 06, 2016 , ... Few ... which made headlines mostly for its cost despite its potential to wipe out ... surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have created fallout in ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
Breaking Medicine News(10 mins):